Erdafitinib
CAS 1346242-81-6 1 FDA-DMF supplierSmall Molecule
Overview
Erdafitinib is an oral fibroblast growth factor receptor (FGFR) kinase inhibitor approved for the treatment of certain types of bladder cancer. It specifically targets genetic alterations in FGFR2 and FGFR3.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Erdafitinib expires 2 Feb 2038 and exclusivity 19 Jan 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.